|
63 Companies |
|
72 Products |
|
72 Products |
|
71 Mechanisms of Action |
|
1 Trial |
|
335 News |
|
| «1234567» |
- || Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Enrollment change, Trial primary completion date: A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma (clinicaltrials.gov) - Jan 17, 2015
P1, N=53, Recruiting, Sponsor: Karyopharm Therapeutics, Inc
N=20 --> 53 | Trial primary completion date: Dec 2013 --> Nov 2015
- | plerixafor / Generic mfg.
Enrollment closed: A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone (clinicaltrials.gov) - Jan 17, 2015
P1/2, N=46, Active, not recruiting, Sponsor: Genzyme, a Sanofi Company
N=20 --> 53 | Trial primary completion date: Dec 2013 --> Nov 2015 Recruiting --> Active, not recruiting
- Pexa-Vec (pexastimogene devacirepvec) / SillaJen, Transgene
Trial completion: Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients (clinicaltrials.gov) - Jan 15, 2015
P1, N=6, Completed, Sponsor: Jennerex Biotherapeutics
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- topotecan / Generic mfg., melphalan / Generic mfg., busulfan / Generic mfg.
Enrollment change, Trial withdrawal: Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed N=15 --> 0 | Recruiting --> Withdrawn
- Trial primary completion date, Metastases: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Dec 24, 2014
P1, N=6, Active, not recruiting, Sponsor: City of Hope Medical Center
N=15 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Feb 2015 --> Feb 2016
- ||| dasatinib / Generic mfg.
Enrollment change, Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Dec 19, 2014
P2, N=386, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
Trial primary completion date: Feb 2015 --> Feb 2016 N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
- melphalan / Generic mfg., busulfan / Generic mfg.
Trial initiation date: A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma (clinicaltrials.gov) - Dec 13, 2014
P1, N=10, Recruiting, Sponsor: University of Louisville
N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015 Initiation date: Oct 2013 --> Apr 2013
- |||| lithium carbonate ER / Generic mfg.
Enrollment open: Li2CO3: Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma (clinicaltrials.gov) - Dec 7, 2014
P4, N=400, Recruiting, Sponsor: Sun Yat-sen University
Initiation date: Oct 2013 --> Apr 2013 Not yet recruiting --> Recruiting
- decitabine / Generic mfg.
Trial primary completion date: Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma (clinicaltrials.gov) - Dec 5, 2014
P1, N=15, Recruiting, Sponsor: University of Louisville
Not yet recruiting --> Recruiting Trial primary completion date: Aug 2014 --> Aug 2015
- Enrollment change, Trial termination, Trial primary completion date, Biopsy: Huntsman Biopsy Study (clinicaltrials.gov) - Nov 25, 2014
P=N/A, N=142, Terminated, Sponsor: State University of New York - Upstate Medical University
Trial primary completion date: Aug 2014 --> Aug 2015 N=100 --> 142 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Feb 2014; Huntmans Cancer Institute terminated study
- ||| Enrollment open, Trial initiation date: Monocyte Phenotypic and Functional Differences (clinicaltrials.gov) - Nov 13, 2014
P=N/A, N=90, Recruiting, Sponsor: Duke University
N=100 --> 142 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2015 --> Feb 2014; Huntmans Cancer Institute terminated study Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Oct 2014 Trial primary completion date: Nov 2014 --> Apr 2015
- dacarbazine / Generic mfg.
Enrollment closed, FDG PET, Metastases: Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma (clinicaltrials.gov) - Nov 7, 2014
P2, N=80, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Nov 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- || Talzenna (talazoparib) / Pfizer
Enrollment closed, Metastases: Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors (clinicaltrials.gov) - Oct 10, 2014
P1, N=85, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Enrollment closed, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Oct 10, 2014
P1b, N=120, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Yondelis (trabectedin) / PharmaMar, J&J
Trial completion: Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=50, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | vinblastine / Generic mfg., celecoxib oral / Generic mfg.
Trial completion, Combination therapy, Metastases: Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors (clinicaltrials.gov) - Sep 28, 2014
P2, N=38, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Enrollment open, Metastases: Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy (clinicaltrials.gov) - Sep 5, 2014
P2, N=36, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- everolimus / Generic mfg., sorafenib / Generic mfg.
Trial completion, Trial primary completion date: SERIO: Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma (clinicaltrials.gov) - Sep 5, 2014
P2, N=38, Completed, Sponsor: Italian Sarcoma Group
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Mar 2014
- Avastin (bevacizumab) / Roche
Phase classification, Enrollment change, Trial primary completion date: Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma (clinicaltrials.gov) - Sep 4, 2014
P2, N=7, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial primary completion date: Jul 2014 --> Mar 2014 Phase classification: P3 --> P2 | N=78 --> 7 | Trial primary completion date: Aug 2008 --> Aug 2009
- Trial termination, Surgery, Metastases: Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone Sarcoma (clinicaltrials.gov) - Aug 29, 2014
P2, N=7, Terminated, Sponsor: City of Hope Medical Center
Phase classification: P3 --> P2 | N=78 --> 7 | Trial primary completion date: Aug 2008 --> Aug 2009 Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor.
- Yondelis (trabectedin) / PharmaMar, J&J
Enrollment change, Metastases: Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 8, 2014
P2b, N=133, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Completed --> Terminated; The study was terminated prematurely due to withdrawal of support by the sponsor. N=370 --> 133
- | lorukafusp alfa (APN301) / Apeiron Biologics
Trial completion, Trial initiation date: Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors (clinicaltrials.gov) - Aug 8, 2014
P1, N=28, Completed, Sponsor: Children's Oncology Group
N=370 --> 133 Active, not recruiting --> Completed | Initiation date: May 2001 --> Oct 2001
- sirolimus / Generic mfg.
Trial primary completion date: Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors (clinicaltrials.gov) - Aug 7, 2014
P1, N=30, Recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed | Initiation date: May 2001 --> Oct 2001 Trial primary completion date: Sep 2014 --> Sep 2016
- ||| Enrollment open: Study of Blood Samples From Patients With Osteosarcoma (clinicaltrials.gov) - Aug 6, 2014
P=N/A, N=1000, Recruiting, Sponsor: Children's Oncology Group
Trial primary completion date: Sep 2014 --> Sep 2016 Active, not recruiting --> Recruiting
- thiotepa / Generic mfg.
Trial primary completion date: OSII-TTP: Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma (clinicaltrials.gov) - Aug 5, 2014
P2, N=66, Recruiting, Sponsor: Centre Leon Berard
Active, not recruiting --> Recruiting Trial primary completion date: Oct 2015 --> Dec 2016
- ||| Trial completion: Genetic Study of Children With Soft Tissue Sarcoma or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=294, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Oct 2015 --> Dec 2016 Active, not recruiting --> Completed
- | dexrazoxane / Generic mfg.
Trial completion, Metastases: Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma (clinicaltrials.gov) - Aug 3, 2014
P3, N=253, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Lonquex (lipegfilgrastim biosimilar) / Teva
Trial completion: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - Aug 1, 2014
P1, N=21, Completed, Sponsor: Merckle GmbH
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Enrollment change: Colony-Stimulating Factors in Treating Children With Recurrent or Refractory Solid Tumors (clinicaltrials.gov) - Jul 24, 2014
P1, N=16, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=24 --> 16
- Trial primary completion date, Metastases: Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants (clinicaltrials.gov) - Jul 23, 2014
P=N/A, N=48, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed | N=24 --> 16 Trial primary completion date: Oct 2009 --> Oct 2015
- | Trial suspension: MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases (clinicaltrials.gov) - Jul 23, 2014
P2, N=52, Suspended, Sponsor: Celsion
Trial primary completion date: Oct 2009 --> Oct 2015 Not yet recruiting --> Suspended
- RG4733 / Roche, Erivedge (vismodegib) / Roche
Trial primary completion date, Combination therapy, Metastases: Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Jul 21, 2014
P1b, N=120, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Suspended Trial primary completion date: Aug 2014 --> Nov 2014
- Vaxira (racotumomab) / Eurofarma, Recombio
Enrollment closed, Trial primary completion date: Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides (clinicaltrials.gov) - Jul 17, 2014
P1, N=15, Active, not recruiting, Sponsor: Laboratorio Elea S.A.C.I.F. y A.
Trial primary completion date: Aug 2014 --> Nov 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Mar 2014
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - Jul 17, 2014
P2, N=378, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2013 --> Mar 2014 Active, not recruiting --> Completed | N=174 --> 378
- Trial primary completion date, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jun 22, 2014
P2, N=3, Terminated, Sponsor: Stanford University
Active, not recruiting --> Completed | N=174 --> 378 Trial primary completion date: Jun 2014 --> Nov 2013
- Trial termination, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jun 22, 2014
P2, N=3, Terminated, Sponsor: Stanford University
Trial primary completion date: Jun 2014 --> Nov 2013 Active, not recruiting --> Terminated; Study did not reach primary objective; study did not accrue enough patients.
- Enrollment change, Trial termination, Trial primary completion date, Metastases: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma (clinicaltrials.gov) - Jun 22, 2014
P2, N=3, Terminated, Sponsor: Stanford University
Active, not recruiting --> Terminated; Study did not reach primary objective; study did not accrue enough patients. N=20 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Nov 2013; Study did not reach primary objective; study did not accrue enough patients.
- || dasatinib / Generic mfg.
Trial primary completion date, Metastases: Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) - Jun 19, 2014
P2, N=502, Active, not recruiting, Sponsor: Sarcoma Alliance for Research through Collaboration
N=20 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2014 --> Nov 2013; Study did not reach primary objective; study did not accrue enough patients. Trial primary completion date: Dec 2013 --> Dec 2014
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change: IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor (clinicaltrials.gov) - Jun 19, 2014
P1, N=34, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2013 --> Dec 2014 N=48 --> 34
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jun 8, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=48 --> 34 N=92 --> 30
- Rytelo (imetelstat) / Geron
Trial initiation date: Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Jun 2, 2014
P2, N=0, Withdrawn, Sponsor: Children's Oncology Group
N=92 --> 30 Initiation date: Jan 2014 --> Jun 2014
- Lonquex (lipegfilgrastim biosimilar) / Teva
Enrollment closed: PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma (clinicaltrials.gov) - May 19, 2014
P1, N=21, Active, not recruiting, Sponsor: Merckle GmbH
Initiation date: Jan 2014 --> Jun 2014 Recruiting --> Active, not recruiting
- calcitriol (BPM 31543) / BPGbio
Trial primary completion date, Metastases: Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) - May 14, 2014
P1, N=18, Recruiting, Sponsor: Berg, LLC
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2013 --> Aug 2014
- calcitriol (BPM 31543) / BPGbio
Trial completion date, Metastases: Compound 31543 (Calcitriol, USP) in Patients Receiving Taxane-based Chemotherapy Regimens for Advanced or Recurrent Disease (clinicaltrials.gov) - May 14, 2014
P1, N=18, Recruiting, Sponsor: Berg, LLC
Trial primary completion date: Aug 2013 --> Aug 2014 Trial completion date: Aug 2013 --> Sep 2014
- Trial primary completion date: Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma (clinicaltrials.gov) - May 12, 2014
P2, N=30, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial completion date: Aug 2013 --> Sep 2014 Trial primary completion date: Mar 2014 --> Mar 2016
- | Mepact (mifamurtide) / Takeda
Trial completion date: Mifamurtide (L-MTP-PE) for High-Risk Osteosarcoma (clinicaltrials.gov) - May 12, 2014
P=N/A, N=205, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Trial primary completion date: Mar 2014 --> Mar 2016 Trial completion date: May 2013 --> Oct 2012
- Clinical: Monocyte Phenotypic and Functional Differences (clinicaltrials.gov) - May 5, 2014
P=N/A, N=90, Not yet recruiting, Sponsor: Duke University
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - May 5, 2014
P2, N=172, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: May 2013 --> Oct 2012 Trial primary completion date: Apr 2014 --> Jul 2014
- cixutumumab (IMC A12) / Eli Lilly
Enrollment change: Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Mar 31, 2014
P2, N=114, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2014 --> Jul 2014 N=160 --> 114